Anti‑Myelin Oligodendrocyte Glycoprotein‑Associated Disease with Recurrent Tumefactive Demyelinating Lesions

References (5)

1. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89‑102
2. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca‑Fernandez A, et al. Clinical presentation and prognosis in MOG‑antibody disease: A UK study. Brain 2017;140:3128‑38
3. Ataka T, Kimura N, Matsubara E. A case of myelin oligodendrocyte glycoprotein‑antibody‑associated disease presenting with tumefactive demyelinating lesion. Mult Scler Relat Disord 2020;43:102191
4. Katsuse K, Kurihara M, Sugiyama Y, Kodama S, Takahashi M, Momose T, et al. Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti‑MOG antibody associated disease. Mult Scler Relat Disord 2019;27:91‑4
5. Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord 2017;14:72‑9.